BACKGROUND: The latest generation of left ventricular assist devices consists of nonpulsatile impeller pumps. In these small pumps, thrombus formation inside the device does not lead to thromboembolic end-organ dysfunction but may dramatically impair pump flow. We report on our experience with thrombus-related pump dysfunctions of the MicroMed DeBakey left ventricular assist device and its treatment. METHODS: Eight of 22 patients with a MicroMed DeBakey VAD presented with a critically reduced pump flow. In 7 cases, an increased power demand indicative of progressive thrombus formation associated with the device was evident, whereas 1 case presented with thrombus formation within the inflow conduit associated with a very low power demand. Brief spontaneously resolving pump stops had been noted in 6 patients. All 8 patients were treated with 100 mg of recombinant tissue plasminogen activator (rt-PA), administered via an IV line. RESULTS: Rt-PA lysis led to an increase of pump flow along with a reduction of power demand within a short time in all patients. No severe bleeding complications occurred. However, 4 patients experienced transient epistaxis. All patients could be discharged from intensive care immediately after discontinuation of thrombolytic therapy. CONCLUSION: Rt-PA lysis is a very effective tool for thrombus-related pump dysfunction in patients with impeller pumps, which renders emergency surgical exchange unnecessary in most cases.
BACKGROUND: The latest generation of left ventricular assist devices consists of nonpulsatile impeller pumps. In these small pumps, thrombus formation inside the device does not lead to thromboembolic end-organ dysfunction but may dramatically impair pump flow. We report on our experience with thrombus-related pump dysfunctions of the MicroMed DeBakey left ventricular assist device and its treatment. METHODS: Eight of 22 patients with a MicroMed DeBakey VAD presented with a critically reduced pump flow. In 7 cases, an increased power demand indicative of progressive thrombus formation associated with the device was evident, whereas 1 case presented with thrombus formation within the inflow conduit associated with a very low power demand. Brief spontaneously resolving pump stops had been noted in 6 patients. All 8 patients were treated with 100 mg of recombinant tissue plasminogen activator (rt-PA), administered via an IV line. RESULTS: Rt-PA lysis led to an increase of pump flow along with a reduction of power demand within a short time in all patients. No severe bleeding complications occurred. However, 4 patients experienced transient epistaxis. All patients could be discharged from intensive care immediately after discontinuation of thrombolytic therapy. CONCLUSION: Rt-PA lysis is a very effective tool for thrombus-related pump dysfunction in patients with impeller pumps, which renders emergency surgical exchange unnecessary in most cases.
Authors: O Wever-Pinzon; J Stehlik; A G Kfoury; J V Terrovitis; N A Diakos; C Charitos; D Y Li; S G Drakos Journal: Pharmacol Ther Date: 2012-01-16 Impact factor: 12.310
Authors: Mark J Russo; Claudia Gidea; Ravi Karanam; David A Baran; Craig R Saunders; Mark J Zucker; Margarita T Camacho Journal: J Extra Corpor Technol Date: 2014-12
Authors: Diana García Sáez; Prashant Mohite; Bartlomeij Zych; Anton Sabashnikov; André R Simon Journal: Interact Cardiovasc Thorac Surg Date: 2013-02-26
Authors: Martin Strüber; Anna L Meyer; Doris Malehsa; Christiane Kugler; Andre R Simon; Axel Haverich Journal: Dtsch Arztebl Int Date: 2009-07-13 Impact factor: 5.594